X0303 4 2009-02-25 1 0001168335 ABBOTT MEDICAL OPTICS INC EYE 0001227310 GALLAGHER ROBERT FRANCIS C/O ABBOTT MEDICAL OPTICS INC. 1700 E. ST. ANDREW PLACE SANTA ANA CA 92705 0 1 0 0 Executive Vice President Common Stock 2009-02-25 4 U 0 22 22.00 D 6291.3833 D Common Stock 2009-02-25 4 U 0 91 22.00 D 6200.3833 D Common Stock 2009-02-26 4 D 0 4400.3833 22.00 D 1800 D Common Stock 2009-02-25 4 F 0 644 22.01 D 1156 D Common Stock 2009-02-26 4 D 0 1156 22.00 D 0 D Common Stock 2009-02-25 4 A 0 2300 0 A 2300 D Common Stock 2009-02-25 4 F 0 823 22.01 D 1477 D Common Stock 2009-02-26 4 D 0 1477 22.00 D 0 D Common Stock 2009-02-25 4 A 0 670 0 A 670 D Common Stock 2009-02-25 4 F 0 240 22.01 D 430 D Common Stock 2009-02-26 4 D 0 430 22.00 D 0 D Common Stock 2009-02-25 4 A 0 600 0 A 600 D Common Stock 2009-02-25 4 F 0 215 22.01 D 385 D Common Stock 2009-02-26 4 D 0 385 22.00 D 0 D Common Stock 2009-02-25 4 A 0 1500 0 A 1500 D Common Stock 2009-02-25 4 F 0 537 22.01 D 963 D Common Stock 2009-02-26 4 D 0 963 22.00 D 0 D Common Stock 2009-02-25 4 A 0 3480 0 A 3480 D Common Stock 2009-02-25 4 F 0 1245 22.01 D 2235 D Common Stock 2009-02-26 4 D 0 2235 22.00 D 0 D Common Stock 2009-02-26 4 D 0 4.1234 22.00 D 0 I Shares had been held by 401(k) Trust Employee Stock Option (Right to Buy) 8.99 2009-02-26 4 D 0 20000 0 D 2006-07-29 2012-07-29 Common Stock 20000 0 D Employee Stock Option (Right to Buy) 13.85 2009-02-26 4 D 0 14000 0 D 2007-04-29 2013-04-29 Common Stock 14000 0 D Employee Stock Option (Right to Buy) 33.72 2009-02-26 4 D 0 15000 0 D 2008-05-20 2014-05-20 Common Stock 15000 0 D Employee Stock Option (Right to Buy) 38.20 2009-02-26 4 D 0 20000 0 D 2009-02-25 2015-05-26 Common Stock 20000 0 D Employee Stock Option (Right to Buy) 22.94 2009-02-26 4 D 0 20550 0 D 2009-02-25 2018-05-29 Common Stock 20550 0 D These shares were tendered to Rainforest Acquisition Inc. ("Purchaser") pursuant to Purchaser?s offer to purchase all of the outstanding shares of Advanced Medical Optics, Inc. (the "Issuer") at a cash purchase price of $22.00 per share, without interest, and subject to any required withholding taxes, subject to the terms described in the Offer to Purchase, filed with the SEC on January 27, 2009, as amended (the "Tender Offer"). Such shares were purchased by Purchaser pursuant to the Tender Offer on February 25, 2009. Includes an aggregate of 4,400.3833 shares of common stock acquired through the issuer's Employee Stock Purchase Plan through February 24, 2009. These shares were canceled pursuant to the Agreement and Plan of Merger, dated January 11, 2009, by and among Abbott Laboratories, Purchaser and the Issuer (the "Merger Agreement"), in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes) at the effective time of the merger. Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units. The exempt restricted stock units (previously reported on Table II) vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger, such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes). This previously reported exempt stock option, which had vested as to 100% of the underlying shares in accordance with its terms, and which is held in the name of the reporting person's family trust, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,205 shares of Abbott Laboratories common stock at an exercise price of $21.92 per share, determined pursuant to a formula set forth in the Merger Agreement. This previously reported exempt stock option, which had vested as to 100% of the underlying shares in accordance with its terms, and which is held in the name of the reporting person's family trust, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 5,744 shares of Abbott Laboratories common stock at an exercise price of $33.76 per share, determined pursuant to a formula set forth in the Merger Agreement. This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 6,154 shares of Abbott Laboratories common stock at an exercise price of $82.19 per share, determined pursuant to a formula set forth in the Merger Agreement. This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,205 shares of Abbott Laboratories common stock at an exercise price of $93.11 per share, determined pursuant to a formula set forth in the Merger Agreement. This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,431 shares of Abbott Laboratories common stock at an exercise price of $55.92 per share, determined pursuant to a formula set forth in the Merger Agreement. Robert F. Gallagher, By: Aimee S. Weisner, Attorney in Fact 2009-02-27